Lithium promotes longevity through GSK3/NRF2-dependent hormesis

Jorge Iván Castillo-Quan, Li Li, Kerri J. Kinghorn, Dobril K. Ivanov, Luke S. Tain, Cathy Slack, Fiona Kerr, Tobias Nespital, Janet Thornton, John Hardy, Ivana Bjedov, Linda Partridge

Research output: Contribution to journalArticle

Abstract

The quest to extend healthspan via pharmacological means is becoming increasingly urgent, both from a health and economic perspective. Here we show that lithium, a drug approved for human use, promotes longevity and healthspan. We demonstrate that lithium extends lifespan in female and male Drosophila, when administered throughout adulthood or only later in life. The life-extending mechanism involves the inhibition of glycogen synthase kinase-3 (GSK-3) and activation of the transcription factor nuclear factor erythroid 2-related factor (NRF-2). Combining genetic loss of the NRF-2 repressor Kelch-like ECH-associated protein 1 (Keap1) with lithium treatment revealed that high levels of NRF-2 activation conferred stress resistance, while low levels additionally promoted longevity. The discovery of GSK-3 as a therapeutic target for aging will likely lead to more effective treatments that can modulate mammalian aging and further improve health in later life.

LanguageEnglish
Pages638-650
Number of pages13
JournalCell Reports
Volume15
Issue number3
Early online date7 Apr 2016
DOIs
Publication statusPublished - 19 Apr 2016

Fingerprint

Hormesis
Lithium
Glycogen Synthase Kinase 3
NF-E2 Transcription Factor
Aging of materials
Chemical activation
Health
Drosophila
Economics
Pharmacology
Pharmaceutical Preparations
Proteins
Therapeutics

Bibliographical note

© 2016 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords

  • aging
  • dietary restriction
  • GSK-3
  • keap1
  • NRF-2
  • triglycerides
  • xenobiotic stress

Cite this

Castillo-Quan, J. I., Li, L., Kinghorn, K. J., Ivanov, D. K., Tain, L. S., Slack, C., ... Partridge, L. (2016). Lithium promotes longevity through GSK3/NRF2-dependent hormesis. 15(3), 638-650. https://doi.org/10.1016/j.celrep.2016.03.041
Castillo-Quan, Jorge Iván ; Li, Li ; Kinghorn, Kerri J. ; Ivanov, Dobril K. ; Tain, Luke S. ; Slack, Cathy ; Kerr, Fiona ; Nespital, Tobias ; Thornton, Janet ; Hardy, John ; Bjedov, Ivana ; Partridge, Linda. / Lithium promotes longevity through GSK3/NRF2-dependent hormesis. 2016 ; Vol. 15, No. 3. pp. 638-650.
@article{f23521cae63a4a08a4d13d63a5210a9c,
title = "Lithium promotes longevity through GSK3/NRF2-dependent hormesis",
abstract = "The quest to extend healthspan via pharmacological means is becoming increasingly urgent, both from a health and economic perspective. Here we show that lithium, a drug approved for human use, promotes longevity and healthspan. We demonstrate that lithium extends lifespan in female and male Drosophila, when administered throughout adulthood or only later in life. The life-extending mechanism involves the inhibition of glycogen synthase kinase-3 (GSK-3) and activation of the transcription factor nuclear factor erythroid 2-related factor (NRF-2). Combining genetic loss of the NRF-2 repressor Kelch-like ECH-associated protein 1 (Keap1) with lithium treatment revealed that high levels of NRF-2 activation conferred stress resistance, while low levels additionally promoted longevity. The discovery of GSK-3 as a therapeutic target for aging will likely lead to more effective treatments that can modulate mammalian aging and further improve health in later life.",
keywords = "aging, dietary restriction, GSK-3, keap1, NRF-2, triglycerides, xenobiotic stress",
author = "Castillo-Quan, {Jorge Iv{\'a}n} and Li Li and Kinghorn, {Kerri J.} and Ivanov, {Dobril K.} and Tain, {Luke S.} and Cathy Slack and Fiona Kerr and Tobias Nespital and Janet Thornton and John Hardy and Ivana Bjedov and Linda Partridge",
note = "{\circledC} 2016 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).",
year = "2016",
month = "4",
day = "19",
doi = "10.1016/j.celrep.2016.03.041",
language = "English",
volume = "15",
pages = "638--650",
number = "3",

}

Castillo-Quan, JI, Li, L, Kinghorn, KJ, Ivanov, DK, Tain, LS, Slack, C, Kerr, F, Nespital, T, Thornton, J, Hardy, J, Bjedov, I & Partridge, L 2016, 'Lithium promotes longevity through GSK3/NRF2-dependent hormesis' vol. 15, no. 3, pp. 638-650. https://doi.org/10.1016/j.celrep.2016.03.041

Lithium promotes longevity through GSK3/NRF2-dependent hormesis. / Castillo-Quan, Jorge Iván; Li, Li; Kinghorn, Kerri J.; Ivanov, Dobril K.; Tain, Luke S.; Slack, Cathy; Kerr, Fiona; Nespital, Tobias; Thornton, Janet; Hardy, John; Bjedov, Ivana; Partridge, Linda.

Vol. 15, No. 3, 19.04.2016, p. 638-650.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lithium promotes longevity through GSK3/NRF2-dependent hormesis

AU - Castillo-Quan, Jorge Iván

AU - Li, Li

AU - Kinghorn, Kerri J.

AU - Ivanov, Dobril K.

AU - Tain, Luke S.

AU - Slack, Cathy

AU - Kerr, Fiona

AU - Nespital, Tobias

AU - Thornton, Janet

AU - Hardy, John

AU - Bjedov, Ivana

AU - Partridge, Linda

N1 - © 2016 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PY - 2016/4/19

Y1 - 2016/4/19

N2 - The quest to extend healthspan via pharmacological means is becoming increasingly urgent, both from a health and economic perspective. Here we show that lithium, a drug approved for human use, promotes longevity and healthspan. We demonstrate that lithium extends lifespan in female and male Drosophila, when administered throughout adulthood or only later in life. The life-extending mechanism involves the inhibition of glycogen synthase kinase-3 (GSK-3) and activation of the transcription factor nuclear factor erythroid 2-related factor (NRF-2). Combining genetic loss of the NRF-2 repressor Kelch-like ECH-associated protein 1 (Keap1) with lithium treatment revealed that high levels of NRF-2 activation conferred stress resistance, while low levels additionally promoted longevity. The discovery of GSK-3 as a therapeutic target for aging will likely lead to more effective treatments that can modulate mammalian aging and further improve health in later life.

AB - The quest to extend healthspan via pharmacological means is becoming increasingly urgent, both from a health and economic perspective. Here we show that lithium, a drug approved for human use, promotes longevity and healthspan. We demonstrate that lithium extends lifespan in female and male Drosophila, when administered throughout adulthood or only later in life. The life-extending mechanism involves the inhibition of glycogen synthase kinase-3 (GSK-3) and activation of the transcription factor nuclear factor erythroid 2-related factor (NRF-2). Combining genetic loss of the NRF-2 repressor Kelch-like ECH-associated protein 1 (Keap1) with lithium treatment revealed that high levels of NRF-2 activation conferred stress resistance, while low levels additionally promoted longevity. The discovery of GSK-3 as a therapeutic target for aging will likely lead to more effective treatments that can modulate mammalian aging and further improve health in later life.

KW - aging

KW - dietary restriction

KW - GSK-3

KW - keap1

KW - NRF-2

KW - triglycerides

KW - xenobiotic stress

UR - http://www.scopus.com/inward/record.url?scp=84962775546&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2016.03.041

DO - 10.1016/j.celrep.2016.03.041

M3 - Article

VL - 15

SP - 638

EP - 650

IS - 3

ER -

Castillo-Quan JI, Li L, Kinghorn KJ, Ivanov DK, Tain LS, Slack C et al. Lithium promotes longevity through GSK3/NRF2-dependent hormesis. 2016 Apr 19;15(3):638-650. https://doi.org/10.1016/j.celrep.2016.03.041